Inside Precision Medicine January 23, 2026
The head of global research described the pharmaceutical company’s efforts to go beyond injectables to include pills, combos, and scalable treatments
Novo Nordisk is doubling down on obesity and diabetes. Speaking with Inside Precision Medicine at the 2026 J.P. Morgan Healthcare Conference, head of research Jacob Petersen said recent internal changes have pushed the company to go deeper—and broader—across both diseases. The aim, Petersen emphasized, is not just incremental weight loss but better cardiovascular, renal, and metabolic outcomes, fewer gastrointestinal side effects, and less frequent dosing. That means Novo Nordisk is expanding beyond injectables into oral options like the newly launched Wegovy pill, while building next-generation combinations spanning incretins GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) and amylins, glucagon,...
Today's Sponsors
Today's Sponsor